Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Lymphoid 1

Conditions

Breast Neoplasms 2Stomach Neoplasms 1Recurrent Squamous Cell Lung Carcinoma 1Neoplasms 1Multiple Myeloma 1Lymphoma 1Hematologic Neoplasms 1FGFR1 Gene Amplification 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Dexamethasone 277Lenalidomide 155Bortezomib 152Cyclophosphamide 115Melphalan 107Calcium Dobesilate 107fludarabine phosphate 70carfilzomib 61pomalidomide 55Peripheral Blood Stem Cell Transplantation 53Whole-Body Irradiation 52Mycophenolic Acid 52Granulocyte Colony-Stimulating Factor 52Filgrastim 52daratumumab 46fludarabine 43Tacrolimus 41ixazomib 40Busulfan 40Thalidomide 36Cyclosporine 32dexamethasone acetate 26Stem Cell Transplantation 26Antilymphocyte Serum 25dexamethasone 21-phosphate 22plerixafor 20auricularum 20belantamab mafodotin 19Prednisone 19Etoposide 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Multiple Myeloma × AZD4547 × Clear all
NCT04439240 2021-06-29

Testing AZD4547 as a Potential Targeted Treatment in Cancers With FGFR Genetic Changes (MATCH-Subprotocol W)

National Cancer Institute (NCI)

Phase 2 Completed
52 enrolled 10 charts
LymphoidOther hematologic neoplasmPlasma cell

Lymphoma, Multiple Myeloma, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡